Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix389 - ix399
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, pp. S115 - S115
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2011, Volume 17, Issue 15, pp. 5060 - 5070
Purpose: We investigated the antitumor activity of the combination of two different humanized monoclonal human epidermal growth factor receptor (HER) 2...
ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | THERAPY | ONCOLOGY | PROGNOSIS | HERCEPTIN | METASTATIC BREAST-CANCER | ERBB SIGNALING NETWORK | HIGH-EXPRESSION | MONOCLONAL-ANTIBODY | HER2 | Stomach Neoplasms - genetics | Receptor, Epidermal Growth Factor - immunology | Cell Proliferation | Humans | Stomach Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal, Humanized - administration & dosage | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Mice, Nude | Cell Line, Tumor | Mice | Trastuzumab
ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | THERAPY | ONCOLOGY | PROGNOSIS | HERCEPTIN | METASTATIC BREAST-CANCER | ERBB SIGNALING NETWORK | HIGH-EXPRESSION | MONOCLONAL-ANTIBODY | HER2 | Stomach Neoplasms - genetics | Receptor, Epidermal Growth Factor - immunology | Cell Proliferation | Humans | Stomach Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal, Humanized - administration & dosage | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Mice, Nude | Cell Line, Tumor | Mice | Trastuzumab
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv421 - iv421
Abstract Aim: Erlotinib (ERL), a specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, benefits patients with non-small cell lung...
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2014, Volume 9, Issue 7, p. e101854
Polyplex micelles have demonstrated biocompatibility and achieve efficient gene transfection in vivo. Here, we investigated a polyplex micelle encapsulating...
CANCER-PATIENTS | COLONY-STIMULATING FACTOR | DENDRITIC CELLS | SART3-DERIVED PEPTIDES | MULTIDISCIPLINARY SCIENCES | PANCREATIC-CANCER | IMMUNE ACTIVATION | PEGYLATED POLYPLEX | BLOCK-COPOLYMER | CYTOTOXIC T-LYMPHOCYTES | PERITONEAL DISSEMINATION | Antigens, Neoplasm - genetics | RNA-Binding Proteins - genetics | Antigens, Neoplasm - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - metabolism | Mice, Inbred C57BL | RNA-Binding Proteins - immunology | Injections, Intraperitoneal | CD40 Ligand - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - genetics | Cancer Vaccines - immunology | Animals | CD40 Ligand - metabolism | Granulocyte-Macrophage Colony-Stimulating Factor - immunology | CD40 Ligand - genetics | Micelles | Antigens, Neoplasm - metabolism | Female | Mice | Mice, Inbred BALB C | RNA-Binding Proteins - metabolism | Cancer vaccines | Squamous cell carcinoma | Histocompatibility antigens | Analysis | Liver | Genes | HLA histocompatibility antigens | Colorectal cancer | T cells | Tumors | Peptides | Cytotoxicity | Vaccines | Immunity | CD40L protein | Cancer therapies | Anticancer properties | Metastases | Surgery | Biocompatibility | Physiology | Natural killer cells | Drug dosages | Deoxyribonucleic acid--DNA | Spleen | CD11c antigen | Antigens | Melanoma | Vectors (Biology) | Chemotherapy | Major histocompatibility complex | Pancreatic cancer | Infiltration | Histocompatibility | Haplotypes | Animal models | Colorectal carcinoma | Antibodies | Clinical trials | Oncology | Lymphocytes T | DNA vaccines | Macrophages | Lymph nodes | Granulocytes | Lymphocytes | Colony-stimulating factor | Engineering schools | Cell survival | Dendritic cells | Granulocyte-macrophage colony-stimulating factor | CD4 antigen | Rejection | Lungs | Plasmids | Antigen (tumor-associated) | In vivo methods and tests | Peritoneum | Deoxyribonucleic acid | DNA
CANCER-PATIENTS | COLONY-STIMULATING FACTOR | DENDRITIC CELLS | SART3-DERIVED PEPTIDES | MULTIDISCIPLINARY SCIENCES | PANCREATIC-CANCER | IMMUNE ACTIVATION | PEGYLATED POLYPLEX | BLOCK-COPOLYMER | CYTOTOXIC T-LYMPHOCYTES | PERITONEAL DISSEMINATION | Antigens, Neoplasm - genetics | RNA-Binding Proteins - genetics | Antigens, Neoplasm - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - metabolism | Mice, Inbred C57BL | RNA-Binding Proteins - immunology | Injections, Intraperitoneal | CD40 Ligand - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - genetics | Cancer Vaccines - immunology | Animals | CD40 Ligand - metabolism | Granulocyte-Macrophage Colony-Stimulating Factor - immunology | CD40 Ligand - genetics | Micelles | Antigens, Neoplasm - metabolism | Female | Mice | Mice, Inbred BALB C | RNA-Binding Proteins - metabolism | Cancer vaccines | Squamous cell carcinoma | Histocompatibility antigens | Analysis | Liver | Genes | HLA histocompatibility antigens | Colorectal cancer | T cells | Tumors | Peptides | Cytotoxicity | Vaccines | Immunity | CD40L protein | Cancer therapies | Anticancer properties | Metastases | Surgery | Biocompatibility | Physiology | Natural killer cells | Drug dosages | Deoxyribonucleic acid--DNA | Spleen | CD11c antigen | Antigens | Melanoma | Vectors (Biology) | Chemotherapy | Major histocompatibility complex | Pancreatic cancer | Infiltration | Histocompatibility | Haplotypes | Animal models | Colorectal carcinoma | Antibodies | Clinical trials | Oncology | Lymphocytes T | DNA vaccines | Macrophages | Lymph nodes | Granulocytes | Lymphocytes | Colony-stimulating factor | Engineering schools | Cell survival | Dendritic cells | Granulocyte-macrophage colony-stimulating factor | CD4 antigen | Rejection | Lungs | Plasmids | Antigen (tumor-associated) | In vivo methods and tests | Peritoneum | Deoxyribonucleic acid | DNA
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2016, Volume 138, Issue 4, pp. 1024 - 1032
Erlotinib (ERL), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, shows notable efficacy against non–small cell lung cancer (NSCLC)...
bevacizumab | MET amplification | erlotinib | T790M mutation | 1ST-LINE TREATMENT | MULTICENTER | VEGF | ACQUIRED-RESISTANCE | OPEN-LABEL | FACTOR RECEPTOR | CHEMOTHERAPY | THERAPY | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | TUMOR-GROWTH | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - genetics | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Erlotinib Hydrochloride - administration & dosage | Immunoblotting | Lung Neoplasms - pathology | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Genes, erbB-1 | Animals | Gene Amplification | Polymerase Chain Reaction | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Mutation | Erlotinib | Analysis | Monoclonal antibodies | Lung cancer, Small cell | Genetic aspects | Cellular signal transduction | Angiogenesis inhibitors | Lung cancer, Non-small cell | Vascular endothelial growth factor | Signal transduction | Growth factors | Lung cancer | Tumors
bevacizumab | MET amplification | erlotinib | T790M mutation | 1ST-LINE TREATMENT | MULTICENTER | VEGF | ACQUIRED-RESISTANCE | OPEN-LABEL | FACTOR RECEPTOR | CHEMOTHERAPY | THERAPY | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | TUMOR-GROWTH | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - genetics | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Erlotinib Hydrochloride - administration & dosage | Immunoblotting | Lung Neoplasms - pathology | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Genes, erbB-1 | Animals | Gene Amplification | Polymerase Chain Reaction | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Mutation | Erlotinib | Analysis | Monoclonal antibodies | Lung cancer, Small cell | Genetic aspects | Cellular signal transduction | Angiogenesis inhibitors | Lung cancer, Non-small cell | Vascular endothelial growth factor | Signal transduction | Growth factors | Lung cancer | Tumors
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2013, Volume 167, Issue 3, pp. 238 - 247
A block/homo-mixed polyplex micelle, comprising of cationic homo polymer: poly{N′-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} P[Asp(DET)] and block copolymer:...
Immunogene therapy | Safety evaluation test in cynomolgus monkeys | Intraperitoneal administration | Peritoneal dissemination | Block/homo polyplex micelle | Granulocyte macrophage colony stimulating factor | CELLS | DRUG-DELIVERY | CANCER | CHEMISTRY, MULTIDISCIPLINARY | PLASMID DNA | PROGRESS | PEGYLATED POLYPLEX | PHARMACOLOGY & PHARMACY | CATIOMER | ACCUMULATION | Pancreatic Neoplasms - metabolism | Humans | Liver - metabolism | Gene Expression Regulation, Neoplastic | Injections, Intraperitoneal | DNA - administration & dosage | Lymph Nodes - metabolism | Macaca fascicularis | Polyethylene Glycols - chemistry | RNA, Messenger - metabolism | Granulocyte-Macrophage Colony-Stimulating Factor - genetics | Animals | Spleen - metabolism | Mice, Nude | Micelles | Pancreatic Neoplasms - immunology | Cell Line, Tumor | Killer Cells, Natural - immunology | Female | Mice | Mice, Inbred BALB C | Proteins - chemistry | Genetic Therapy - methods | Pancreatic Neoplasms - therapy | Safety and security measures | Genes | Fibrinogen | Genetic research | Exhibitions | Monkeys | Macrophage colony stimulating factor | Gene therapy | Gene expression | Polyols | Animal models
Immunogene therapy | Safety evaluation test in cynomolgus monkeys | Intraperitoneal administration | Peritoneal dissemination | Block/homo polyplex micelle | Granulocyte macrophage colony stimulating factor | CELLS | DRUG-DELIVERY | CANCER | CHEMISTRY, MULTIDISCIPLINARY | PLASMID DNA | PROGRESS | PEGYLATED POLYPLEX | PHARMACOLOGY & PHARMACY | CATIOMER | ACCUMULATION | Pancreatic Neoplasms - metabolism | Humans | Liver - metabolism | Gene Expression Regulation, Neoplastic | Injections, Intraperitoneal | DNA - administration & dosage | Lymph Nodes - metabolism | Macaca fascicularis | Polyethylene Glycols - chemistry | RNA, Messenger - metabolism | Granulocyte-Macrophage Colony-Stimulating Factor - genetics | Animals | Spleen - metabolism | Mice, Nude | Micelles | Pancreatic Neoplasms - immunology | Cell Line, Tumor | Killer Cells, Natural - immunology | Female | Mice | Mice, Inbred BALB C | Proteins - chemistry | Genetic Therapy - methods | Pancreatic Neoplasms - therapy | Safety and security measures | Genes | Fibrinogen | Genetic research | Exhibitions | Monkeys | Macrophage colony stimulating factor | Gene therapy | Gene expression | Polyols | Animal models
Journal Article
Clinical & Experimental Metastasis, ISSN 0262-0898, 10/2011, Volume 28, Issue 7, pp. 649 - 659
Previous preclinical and clinical findings have suggested a potential role of epidermal growth factor receptor (EGFR) in osteoclast differentiation and the...
Biomedicine | Hematology | Tyrosine kinase inhibitor | Oncology | Cancer Research | Osteoclast | Osteolytic bone invasion model | Surgical Oncology | Biomedicine general | Epidermal growth factor receptor | NUDE-MICE | GEFITINIB | REGULATES OSTEOCLAST DIFFERENTIATION | METASTASIS | KINASE INHIBITORS | TUMOR-CELLS | DEFICIENT MICE | ANTITUMOR-ACTIVITY | BREAST-CANCER | ONCOLOGY | GROWTH | Erlotinib Hydrochloride | Humans | Bone Neoplasms - secondary | Male | Bone Neoplasms - pathology | Osteolysis - drug therapy | Bone Neoplasms - metabolism | Receptor, Epidermal Growth Factor - metabolism | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Invasiveness - pathology | Bone Neoplasms - drug therapy | Osteolysis - pathology | Disease Models, Animal | Carcinoma, Non-Small-Cell Lung - pathology | Osteoblasts - drug effects | Osteolysis - metabolism | Osteoblasts - pathology | Animals | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Osteoblasts - metabolism | Quinazolines - pharmacology | Tyrosine | Epidermal growth factor | Erlotinib | Analysis | Oncology, Experimental | Metastasis | Research | Lung cancer, Non-small cell | Vascular endothelial growth factor | Cancer | Research Paper
Biomedicine | Hematology | Tyrosine kinase inhibitor | Oncology | Cancer Research | Osteoclast | Osteolytic bone invasion model | Surgical Oncology | Biomedicine general | Epidermal growth factor receptor | NUDE-MICE | GEFITINIB | REGULATES OSTEOCLAST DIFFERENTIATION | METASTASIS | KINASE INHIBITORS | TUMOR-CELLS | DEFICIENT MICE | ANTITUMOR-ACTIVITY | BREAST-CANCER | ONCOLOGY | GROWTH | Erlotinib Hydrochloride | Humans | Bone Neoplasms - secondary | Male | Bone Neoplasms - pathology | Osteolysis - drug therapy | Bone Neoplasms - metabolism | Receptor, Epidermal Growth Factor - metabolism | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Invasiveness - pathology | Bone Neoplasms - drug therapy | Osteolysis - pathology | Disease Models, Animal | Carcinoma, Non-Small-Cell Lung - pathology | Osteoblasts - drug effects | Osteolysis - metabolism | Osteoblasts - pathology | Animals | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Osteoblasts - metabolism | Quinazolines - pharmacology | Tyrosine | Epidermal growth factor | Erlotinib | Analysis | Oncology, Experimental | Metastasis | Research | Lung cancer, Non-small cell | Vascular endothelial growth factor | Cancer | Research Paper
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 08/2010, Volume 21, Issue 7, pp. 687 - 694
It has been reported that bevacizumab in combination with paclitaxel significantly prolongs progression-free survival compared with paclitaxel alone in the...
lung cancer | paclitaxel | xenograft model | drug delivery to tumor | bevacizumab | breast cancer | combination therapy | vascular permeability | GROWTH-FACTOR TREATMENT | ANGIOGENESIS | ANTIBODY | THERAPY | ONCOLOGY | VASCULATURE | PHARMACOLOGY & PHARMACY | TUMOR-GROWTH | Tissue Distribution - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Paclitaxel - pharmacokinetics | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Bevacizumab | Drug Synergism | Xenograft Model Antitumor Assays | Antibodies, Monoclonal, Humanized | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Membrane Permeability - drug effects | Female | Mice | Paclitaxel - administration & dosage
lung cancer | paclitaxel | xenograft model | drug delivery to tumor | bevacizumab | breast cancer | combination therapy | vascular permeability | GROWTH-FACTOR TREATMENT | ANGIOGENESIS | ANTIBODY | THERAPY | ONCOLOGY | VASCULATURE | PHARMACOLOGY & PHARMACY | TUMOR-GROWTH | Tissue Distribution - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Paclitaxel - pharmacokinetics | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Bevacizumab | Drug Synergism | Xenograft Model Antitumor Assays | Antibodies, Monoclonal, Humanized | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Membrane Permeability - drug effects | Female | Mice | Paclitaxel - administration & dosage
Journal Article
International Journal of Oncology, ISSN 1019-6439, 08/2017, Volume 51, Issue 2, pp. 425 - 434
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows superior efficacy in patients with non-small cell lung cancer...
EGFR mutation | Erlotinib | VEGF | Bevacizumab | 1ST-LINE TREATMENT | erlotinib | ACQUIRED-RESISTANCE | OPEN-LABEL | VASCULAR-PERMEABILITY | TUMOR ANGIOGENESIS | FACTOR RECEPTOR | CELL LUNG-CANCER | ONCOLOGY | IN-VIVO | bevacizumab | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Non-Small-Cell Lung - pathology | Receptor, Epidermal Growth Factor - genetics | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Erlotinib Hydrochloride - administration & dosage | Antineoplastic Combined Chemotherapy Protocols | Vascular Endothelial Growth Factor A - genetics | Xenograft Model Antitumor Assays | Disease-Free Survival | Animals | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug Resistance, Neoplasm - drug effects
EGFR mutation | Erlotinib | VEGF | Bevacizumab | 1ST-LINE TREATMENT | erlotinib | ACQUIRED-RESISTANCE | OPEN-LABEL | VASCULAR-PERMEABILITY | TUMOR ANGIOGENESIS | FACTOR RECEPTOR | CELL LUNG-CANCER | ONCOLOGY | IN-VIVO | bevacizumab | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Non-Small-Cell Lung - pathology | Receptor, Epidermal Growth Factor - genetics | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Erlotinib Hydrochloride - administration & dosage | Antineoplastic Combined Chemotherapy Protocols | Vascular Endothelial Growth Factor A - genetics | Xenograft Model Antitumor Assays | Disease-Free Survival | Animals | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug Resistance, Neoplasm - drug effects
Journal Article
BioMed Research International, ISSN 2314-6133, 2017, Volume 2017, pp. 7694202 - 7
Despite the recent development of immunotherapies that target programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) in non-small cell lung cancer...
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | AMPLIFICATION | NSCLC | PATHWAY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IMMUNE ESCAPE | ACQUIRED-RESISTANCE | PD-L1 | RECEPTOR | INHIBITORS | MUTATIONS | Cancer patients | Gene mutations | Genetic aspects | Research | Diagnosis | Lung cancer, Non-small cell | Health aspects | Immunohistochemistry | Flow cytometry | Biotechnology | Phosphorylation | Thoracic surgery | PD-1 protein | Lung cancer | Oncology | Kinases | c-Met protein | Proteins | Epidermal growth factor | Immunotherapy | Protein-tyrosine kinase | Tyrosine | Medical research | Immunoglobulins | Epidermal growth factor receptors | Cloning | Mortality | Non-small cell lung carcinoma | L1 protein | Tumor cell lines | Gene amplification | Molecular modelling | PD-L1 protein | Protein expression | Ligands | Death | Mutation | Cancer | Apoptosis | Tumors
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | AMPLIFICATION | NSCLC | PATHWAY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IMMUNE ESCAPE | ACQUIRED-RESISTANCE | PD-L1 | RECEPTOR | INHIBITORS | MUTATIONS | Cancer patients | Gene mutations | Genetic aspects | Research | Diagnosis | Lung cancer, Non-small cell | Health aspects | Immunohistochemistry | Flow cytometry | Biotechnology | Phosphorylation | Thoracic surgery | PD-1 protein | Lung cancer | Oncology | Kinases | c-Met protein | Proteins | Epidermal growth factor | Immunotherapy | Protein-tyrosine kinase | Tyrosine | Medical research | Immunoglobulins | Epidermal growth factor receptors | Cloning | Mortality | Non-small cell lung carcinoma | L1 protein | Tumor cell lines | Gene amplification | Molecular modelling | PD-L1 protein | Protein expression | Ligands | Death | Mutation | Cancer | Apoptosis | Tumors
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, pp. S611 - S612
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 01/2019, Volume 17, Issue 1, pp. 212 - 224
The mechanisms responsible for the development of resistance to alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, are still unclear,...
SARACATINIB AZD0530 | GEFITINIB | ONCOGENE | ONCOLOGY | SRC | EML4-ALK FUSION GENE | ACQUIRED-RESISTANCE | CRIZOTINIB | OPEN-LABEL | INHIBITOR | PHASE-I | CELL BIOLOGY
SARACATINIB AZD0530 | GEFITINIB | ONCOGENE | ONCOLOGY | SRC | EML4-ALK FUSION GENE | ACQUIRED-RESISTANCE | CRIZOTINIB | OPEN-LABEL | INHIBITOR | PHASE-I | CELL BIOLOGY
Journal Article
Human Molecular Genetics, ISSN 0964-6906, 08/2005, Volume 14, Issue 16, pp. 2305 - 2321
A major goal of current human genome-wide studies is to identify the genetic basis of complex disorders. However, the availability of an unbiased, reliable,...
TUMOR-NECROSIS-FACTOR | TENASCIN-X | HLA-DRB1 ALLELES | BIOCHEMISTRY & MOLECULAR BIOLOGY | DETECT LINKAGE DISEQUILIBRIUM | HAPLOTYPE BLOCKS | DISEASE | GENETICS & HEREDITY | MAJOR HISTOCOMPATIBILITY COMPLEX | SUSCEPTIBILITY LOCUS | MARKER CHARACTERISTICS | SNP MARKERS | Genetic Predisposition to Disease - genetics | Major Histocompatibility Complex - genetics | Humans | Middle Aged | Genotype | Male | Chromosome Mapping | Case-Control Studies | Microsatellite Repeats - genetics | DNA - genetics | Arthritis, Rheumatoid - genetics | Polymorphism, Single Nucleotide - genetics | Female | Genome, Human | Genetic Linkage
TUMOR-NECROSIS-FACTOR | TENASCIN-X | HLA-DRB1 ALLELES | BIOCHEMISTRY & MOLECULAR BIOLOGY | DETECT LINKAGE DISEQUILIBRIUM | HAPLOTYPE BLOCKS | DISEASE | GENETICS & HEREDITY | MAJOR HISTOCOMPATIBILITY COMPLEX | SUSCEPTIBILITY LOCUS | MARKER CHARACTERISTICS | SNP MARKERS | Genetic Predisposition to Disease - genetics | Major Histocompatibility Complex - genetics | Humans | Middle Aged | Genotype | Male | Chromosome Mapping | Case-Control Studies | Microsatellite Repeats - genetics | DNA - genetics | Arthritis, Rheumatoid - genetics | Polymorphism, Single Nucleotide - genetics | Female | Genome, Human | Genetic Linkage
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2019, Volume 83, Issue 4, pp. 659 - 671
Trastuzumab emtansine (T-DM1) provides clinical benefit in breast cancers overexpressing human epidermal growth factor receptor 2 (HER2). However, its efficacy...
Trastuzumab emtansine | Medicine & Public Health | Biliary tract cancer | Oncology | Cancer Research | T-DM1 | Pharmacology/Toxicology | HER2 | COMBINATION | PERTUZUMAB | HER2-POSITIVE BREAST-CANCER | THERAPY | ONCOLOGY | GASTRIC-CANCER | ENHANCED ANTITUMOR-ACTIVITY | GROWTH | GENE AMPLIFICATION | PHARMACOLOGY & PHARMACY | Immunohistochemistry | Antimitotic agents | Viral antibodies | Medical research | Epidermal growth factor | Analysis | Medicine, Experimental | Antibodies | Antineoplastic agents | Gallbladder cancer | Biopharmaceutics | Cancer | Biliary tract | Cell culture | Biotechnology | Animal models | Toxicity | Xenotransplantation | Fluorescence | Cytotoxicity | Hybridization | Kinases | Tissues | Cell surface | Anticancer properties | Cell cycle | Fluorescence in situ hybridization | Xenografts | Gallbladder | Inhibition | Growth factors | Cholangiocarcinoma | Antibody-dependent cell-mediated cytotoxicity | Breast cancer | Tumor cell lines | ErbB-2 protein | Signaling | Cell lines | Antitumor activity | Trastuzumab | Apoptosis
Trastuzumab emtansine | Medicine & Public Health | Biliary tract cancer | Oncology | Cancer Research | T-DM1 | Pharmacology/Toxicology | HER2 | COMBINATION | PERTUZUMAB | HER2-POSITIVE BREAST-CANCER | THERAPY | ONCOLOGY | GASTRIC-CANCER | ENHANCED ANTITUMOR-ACTIVITY | GROWTH | GENE AMPLIFICATION | PHARMACOLOGY & PHARMACY | Immunohistochemistry | Antimitotic agents | Viral antibodies | Medical research | Epidermal growth factor | Analysis | Medicine, Experimental | Antibodies | Antineoplastic agents | Gallbladder cancer | Biopharmaceutics | Cancer | Biliary tract | Cell culture | Biotechnology | Animal models | Toxicity | Xenotransplantation | Fluorescence | Cytotoxicity | Hybridization | Kinases | Tissues | Cell surface | Anticancer properties | Cell cycle | Fluorescence in situ hybridization | Xenografts | Gallbladder | Inhibition | Growth factors | Cholangiocarcinoma | Antibody-dependent cell-mediated cytotoxicity | Breast cancer | Tumor cell lines | ErbB-2 protein | Signaling | Cell lines | Antitumor activity | Trastuzumab | Apoptosis
Journal Article
HUMAN MOLECULAR GENETICS, ISSN 0964-6906, 06/2001, Volume 10, Issue 13, pp. 1379 - 1386
Autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT), is caused by multiple genetic and environmental factors....
CTLA-4 GENE POLYMORPHISM | CAUCASIAN POPULATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANDIDATE GENES | CONGENITAL GOITER | GENETICS & HEREDITY | GRAVES-DISEASE | MICROSATELLITE MARKERS | HLA-A | GENOME-WIDE SEARCH | CHROMOSOME 18Q21 | ASSOCIATION
CTLA-4 GENE POLYMORPHISM | CAUCASIAN POPULATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANDIDATE GENES | CONGENITAL GOITER | GENETICS & HEREDITY | GRAVES-DISEASE | MICROSATELLITE MARKERS | HLA-A | GENOME-WIDE SEARCH | CHROMOSOME 18Q21 | ASSOCIATION
Journal Article
Human Molecular Genetics, ISSN 0964-6906, 06/2001, Volume 10, Issue 13, pp. 1379 - 1386
Autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT), is caused by multiple genetic and environmental factors....
Chromosomes, Human, Pair 8 - genetics | Genetic Predisposition to Disease - genetics | Humans | Japan | Family Health | Male | Chromosome Mapping | HLA Antigens - genetics | Thyroiditis, Autoimmune - genetics | Lod Score | Autoimmune Diseases - genetics | CTLA-4 Antigen | Graves Disease - genetics | Abatacept | Immunoconjugates | Thyroid Diseases - genetics | Female | Antigens, Differentiation - genetics | Microsatellite Repeats | Antigens, CD | Chromosomes, Human, Pair 5 - genetics | Genetic Linkage
Chromosomes, Human, Pair 8 - genetics | Genetic Predisposition to Disease - genetics | Humans | Japan | Family Health | Male | Chromosome Mapping | HLA Antigens - genetics | Thyroiditis, Autoimmune - genetics | Lod Score | Autoimmune Diseases - genetics | CTLA-4 Antigen | Graves Disease - genetics | Abatacept | Immunoconjugates | Thyroid Diseases - genetics | Female | Antigens, Differentiation - genetics | Microsatellite Repeats | Antigens, CD | Chromosomes, Human, Pair 5 - genetics | Genetic Linkage
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2013, Volume 24, Issue suppl 9, pp. ix69 - ix69
Journal Article
Anticancer Research, ISSN 0250-7005, 06/2015, Volume 35, Issue 6, pp. 3585 - 3589
Complete video-assisted thoracoscopic surgery (c-VATS) for lung cancer is minimally invasive because of the small incision required. c-VATS has recently become...
T2 and T3 | VATS | Non-small cell lung cancer | non-small cell lung cancer | FEASIBILITY | ONCOLOGY | THORACIC-SURGERY | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - surgery | Humans | Middle Aged | Postoperative Period | Lung Neoplasms - pathology | Male | Thoracic Surgery, Video-Assisted - adverse effects | Thoracic Surgery, Video-Assisted - methods | Aged, 80 and over | Female | Lung Neoplasms - surgery | Aged | Neoplasm Staging
T2 and T3 | VATS | Non-small cell lung cancer | non-small cell lung cancer | FEASIBILITY | ONCOLOGY | THORACIC-SURGERY | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - surgery | Humans | Middle Aged | Postoperative Period | Lung Neoplasms - pathology | Male | Thoracic Surgery, Video-Assisted - adverse effects | Thoracic Surgery, Video-Assisted - methods | Aged, 80 and over | Female | Lung Neoplasms - surgery | Aged | Neoplasm Staging
Journal Article
Human Molecular Genetics, ISSN 0964-6906, 10/2004, Volume 13, Issue 19, pp. 2221 - 2231
Autoimmune thyroid disease (AITD) is caused by an immune response to self-thyroid antigens and has a significant genetic component. Antisense RNA transcripts...
X-INACTIVATION | DANISH TWINS | NONCODING RNAS | CPG ISLAND | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENETICS & HEREDITY | REGULATORY GENE CTLA4 | GRAVES-DISEASE | TSIX | HASHIMOTOS-THYROIDITIS | ASSOCIATION | IMPRINTED GENES | Chromosomes, Human, Pair 8 - genetics | Genetic Predisposition to Disease - genetics | Humans | Thyroiditis, Autoimmune - diagnosis | Polymorphism, Single Nucleotide - genetics | Zinc Fingers - genetics | DNA-Binding Proteins - genetics | DNA, Antisense - genetics | Promoter Regions, Genetic - genetics | Thyroiditis, Autoimmune - genetics | B-Lymphocytes - metabolism | Case-Control Studies
X-INACTIVATION | DANISH TWINS | NONCODING RNAS | CPG ISLAND | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENETICS & HEREDITY | REGULATORY GENE CTLA4 | GRAVES-DISEASE | TSIX | HASHIMOTOS-THYROIDITIS | ASSOCIATION | IMPRINTED GENES | Chromosomes, Human, Pair 8 - genetics | Genetic Predisposition to Disease - genetics | Humans | Thyroiditis, Autoimmune - diagnosis | Polymorphism, Single Nucleotide - genetics | Zinc Fingers - genetics | DNA-Binding Proteins - genetics | DNA, Antisense - genetics | Promoter Regions, Genetic - genetics | Thyroiditis, Autoimmune - genetics | B-Lymphocytes - metabolism | Case-Control Studies
Journal Article